COLUMBUS, Ohio--(

俄亥俄州哥伦布--(

BUSINESS WIRE

商业热线

)--DNA Nanobots, a biotechnology leader in DNA nanoparticles engineered for targeted therapeutics, announced today that Dr. John C. Byrd, M.D., has joined its scientific advisory board (SAB). Byrd is an internationally recognized physician scientist who played significant roles in the translational research and development of several impactful new therapies in blood cell cancers.

)--DNA纳米机器人是为靶向治疗设计的DNA纳米颗粒的生物技术领导者，今天宣布，医学博士约翰·C·伯德博士已加入其科学顾问委员会（SAB）。伯德是一位国际公认的医学科学家，在血细胞癌的几种有影响力的新疗法的转化研究和开发中发挥了重要作用。

Byrd has collaborated with DNA Nanobots founding scientists for over 10 years and will continue to help guide the pre-clinical development. Byrd brings the translational expertise to develop DNA Nanobots’ own therapeutic products pipeline and advise on customizable solutions for biopharma partners to improve targeted delivery of therapeutic payloads (see .

伯德与DNA纳米机器人创始科学家合作了10多年，并将继续帮助指导临床前开发。伯德带来了转化专业知识，以开发DNA纳米机器人自己的治疗产品管道，并为生物制药合作伙伴提供可定制的解决方案，以改进治疗有效载荷的定向交付（请参阅）。

https://dnananobots.com/BPP

https://dnananobots.com/BPP

).

).

Dr. Byrd is Chair of the Department of Internal Medicine at the University of Cincinnati and holds the Gordon and Helen Hughes Taylor Chair, previously a Distinguished University Professor at Ohio State. Byrd is currently a principal and Chief Medical Officer of Beat AML, an LLC of the Leukemia and Lymphoma Society.

伯德博士是辛辛那提大学内科系主任，并担任戈登·休斯·泰勒（Gordon and HelenHughes-Taylor）教授，曾任俄亥俄州立大学杰出教授。伯德目前是白血病和淋巴瘤协会有限责任公司Beat AML的首席和首席医疗官。

Dr. Byrd has over 600 publications and leads a translational laboratory focused on hematologic malignancies, including AML and CLL. Dr. Byrd had critical roles in clinical development and FDA approval of numerous therapeutic agents including breakthrough medicines, rituximab and ibrutinib..

伯德博士拥有600多篇出版物，并领导一个专注于血液系统恶性肿瘤（包括AML和CLL）的转化实验室。伯德博士在临床开发和FDA批准许多治疗药物（包括突破性药物、利妥昔单抗和依鲁替尼）方面发挥了关键作用。。

“I am excited to formalize my long-term relationship with DNA Nanobots and its scientific founders as a member of its scientific advisory board. I believe that their programmable DNA nanoparticle technology offers great promise to improve the way oncology drugs and immunotherapies are designed and developed to create more effective therapies,” Byrd said..

伯德说：“我很高兴能够正式确定我与DNA纳米机器人及其科学创始人之间的长期关系，成为其科学顾问委员会的成员。我相信他们的可编程DNA纳米颗粒技术为改进肿瘤药物和免疫疗法的设计和开发方式，创造更有效的疗法提供了巨大的希望。”。。

DNA Nanobots recently licensed a portfolio of intellectual property on DNA origami for biomedical applications from The Ohio State University, invented by Dr. Carlos E. Castro, Ph.D., Professor and Ralph W. Kurtz Chair in Mechanical Engineering, and researchers in his lab. Castro, who is also on the SAB, said “We’ve had a great working relationship with Dr.

DNA纳米机器人（DNA Nanobots）最近授权俄亥俄州立大学（Ohio State University）的DNA折纸知识产权组合用于生物医学应用，该组合由机械工程教授卡洛斯·卡斯特罗（CarlosE.Castro）博士和拉尔夫·库尔茨（RalphW.Kurtz）主席及其实验室的研究人员发明。卡斯特罗（Castro）也是SAB的成员，他说“我们与Dr。

Byrd for over ten years, and he has been instrumental in guiding our Nanobot platforms for pre-clinical development. We look forward to his expertise and collaboration.”.

伯德十多年来一直在指导我们的纳米机器人平台进行临床前开发。我们期待着他的专业知识和合作。”。

“We are extremely fortunate to have Dr. John Byrd on our team to advise on the pre-clinical development of our own cancer therapeutics, inform clinical trial design, and regulatory strategies, and on improving performance for our biopharma partners,” said DNA Nanobots CEO, Jim Lynch, Ph.D. “Many therapeutics work in the lab but fail in the clinic, and we aim to improve the odds.”.

DNA纳米机器人首席执行官吉姆·林奇博士说：“我们非常幸运地有约翰·伯德博士加入我们的团队，为我们自己的癌症治疗药物的临床前开发提供建议，为临床试验设计和监管策略提供信息，并改进我们生物制药合作伙伴的表现。许多治疗药物在实验室工作，但在临床上却失败了，我们的目标是提高几率。”。

About DNA Nanobots

关于DNA纳米机器人

DNA Nanobots is a platform biotechnology company pioneering customizable DNA nanoparticles to address targeted drug delivery. We engineer custom tissue-targeted solutions for partners to deliver a variety of therapeutics, while developing our own pipeline for cancer and rare diseases. For more information on how DNA Nanobots is revolutionizing therapeutics development and delivery, visit .

DNA纳米机器人是一家平台生物技术公司，开创了可定制的DNA纳米颗粒，以解决靶向药物输送问题。我们为合作伙伴设计定制的组织靶向解决方案，以提供各种治疗方法，同时开发我们自己的癌症和罕见疾病管道。有关DNA纳米机器人如何彻底改变治疗开发和交付的更多信息，请访问。

https://dnananobots.com

https://dnananobots.com

.

.